GSK plc (LON:GSK)
London · Delayed Price · Currency is GBP · Price in GBX 2,250.00
+28.77 (1.30%)
At close: Feb 18, 2026
GSK plc Employees
GSK plc had 68,629 employees as of December 31, 2024. The number of employees decreased by 1,583 or -2.25% compared to the previous year.
Employees
68,629
Change (1Y)
-1,583
Growth (1Y)
-2.25%
Revenue / Employee
475.99K GBP
Profits / Employee
83.29K GBP
Market Cap
89.85B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 68,629 | -1,583 | -2.25% |
| Dec 31, 2023 | 70,212 | 812 | 1.17% |
| Dec 31, 2022 | 69,400 | -20,696 | -22.97% |
| Dec 31, 2021 | 90,096 | -3,970 | -4.22% |
| Dec 31, 2020 | 94,066 | -5,371 | -5.40% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| AstraZeneca | 94,300 |
| Haleon | 24,561 |
| Smith & Nephew | 17,000 |
| Spire Healthcare Group | 15,703 |
| Convatec Group | 10,000 |
| Hikma Pharmaceuticals | 9,500 |
| CVS Group | 8,850 |
| Genus | 3,190 |
GSK plc News
- 3 hours ago - Ex-Dividend Reminder: Shell, Patria Investments and Glaxosmithkline - Nasdaq
- 6 hours ago - GSK's AREXVY Associated With Reductions in Certain RSV-Related Risks Including Heart Attack, Stroke and Severe Flare-Ups of COPD and Asthma, Real World Study Shows - Business Wire
- 1 day ago - GSK: Post-Pivot Buoyancy Set To Continue After Strong 2025 (Upgrade) - Seeking Alpha
- 1 day ago - GSK's Arexvy Vaccine Shows Strong Effectiveness in Real-World Study - GuruFocus
- 1 day ago - GSK says RSV shot Arexvy lowers risk of CV events, asthma, and COPD - Seeking Alpha
- 1 day ago - GSK wins approval of Exdensur in Europe for severe asthma - Seeking Alpha
- 1 day ago - GSK Reports Promising Data for RSV Vaccine Effectiveness - GuruFocus
- 1 day ago - Europe Clears GSK's New Twice-Yearly Asthma Treatment - Benzinga